Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Breast Cancer – Pipeline Review, H2 2016, provides an overview of the Breast Cancer (Oncology) pipeline landscape.
Breast cancer is a cancer that develops from breast cells. Breast cancer usually starts off in the inner lining of milk ducts or the lobules that supply them with milk. Risk factors of breast cancer includes age, beginning of periods before the age of twelve or going through menopause after the age of fifty-five, being overweight, using hormone replacement therapy, consumption of birth control pills and consumption of alcohol. Symptoms include a lump in the breast, a change in size or shape of the breast or discharge from a nipple. Treatment includes radiation, lumpectomy, mastectomy, chemotherapy and hormone therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Breast Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Breast Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Breast Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 45, 158, 167, 2, 13, 474, 96 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 16, 17, 1, 150 and 44 molecules, respectively.
Breast Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Breast Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Breast Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Breast Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Breast Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Breast Cancer (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Breast Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Breast Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
3-D Matrix Ltd
3-V Biosciences Inc
3SBio Inc
4SC AG
A&G Pharmaceutical Inc
AB Science SA
AbbVie Inc
AbGenomics International Inc
Acceleron Pharma Inc
Acetylon Pharmaceuticals Inc
Adaptimmune Therapeutics Plc
ADC Therapeutics Sarl
Adgero Biopharmaceuticals Inc
Aduro BioTech Inc
Advanced Accelerator Applications SA
Advanced Cancer Therapeutics
Advanced Proteome Therapeutics Corp
Advantagene Inc
Advaxis Inc
Advenchen Laboratories LLC
Aegis Therapeutics LLC
Aeglea BioTherapeutics Inc
Aerpio Therapeutics Inc
Aeterna Zentaris Inc
Affichem SA
Agenus Inc
Agilvax Inc
Aileron Therapeutics Inc
Alchemia Ltd
Alethia Biotherapeutics Inc
Alissa Pharma
Almac Discovery Ltd
Alteogen Inc
Amarna Therapeutics BV
Ambrx Inc
American Gene Technologies International Inc
Amgen Inc
Ampio Pharmaceuticals Inc
Amplyx Pharmaceuticals Inc
Angion Biomedica Corp
ANP Technologies Inc
AntiCancer Inc
Antigen Express Inc
Antoxis Ltd
Aphios Corp
APIM Therapeutics AS
Aptevo Therapeutics Inc
Aravive Biologics Inc
ARMO Biosciences Inc
Armour Therapeutics Inc
Arno Therapeutics Inc
ArQule Inc
Arrien Pharmaceuticals LLC
Arvinas Inc
Asana BioSciences LLC
Ascentage Pharma Group Corp Ltd
AskAt Inc
Aslan Pharmaceuticals Pte Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Athenex Inc
ATLAB Pharma SAS
Atossa Genetics Inc
AVEO Pharmaceuticals Inc
Avexxin AS
Azaya Therapeutics Inc
Basilea Pharmaceutica Ltd
Batu Biologics Inc
Bavarian Nordic A/S
Bayer AG
BCN Biosciences LLC
BeiGene Ltd
Bellicum Pharmaceuticals Inc
Berg LLC
BerGenBio AS
Beta Pharma Inc
Bexion Pharmaceuticals LLC
BeyondSpring Pharmaceuticals Inc
Bicycle Therapeutics Ltd
Bio-Path Holdings Inc
'
Table of Contents
Table of Contents 2
Introduction 19
Breast Cancer Overview 20
Therapeutics Development 21
Breast Cancer - Therapeutics under Development by Companies 23
Breast Cancer - Therapeutics under Investigation by Universities/Institutes 66
Breast Cancer - Pipeline Products Glance 75
Breast Cancer - Products under Development by Companies 79
Breast Cancer - Products under Investigation by Universities/Institutes 145
Breast Cancer - Companies Involved in Therapeutics Development 160
Breast Cancer - Therapeutics Assessment 617
Drug Profiles 713
Breast Cancer - Dormant Projects 2934
Breast Cancer - Discontinued Products 3000
Breast Cancer - Product Development Milestones 3013
Appendix 3027
List of Tables
Number of Products under Development for Breast Cancer, H2 2016 142
Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2016 143
Number of Products under Development by Companies, H2 2016 145
Number of Products under Development by Companies, H2 2016 (Contd..1) 146
Number of Products under Development by Companies, H2 2016 (Contd..2) 147
Number of Products under Development by Companies, H2 2016 (Contd..3) 148
Number of Products under Development by Companies, H2 2016 (Contd..4) 149
Number of Products under Development by Companies, H2 2016 (Contd..5) 150
Number of Products under Development by Companies, H2 2016 (Contd..6) 151
Number of Products under Development by Companies, H2 2016 (Contd..7) 152
Number of Products under Development by Companies, H2 2016 (Contd..8) 153
Number of Products under Development by Companies, H2 2016 (Contd..9) 154
Number of Products under Development by Companies, H2 2016 (Contd..10) 155
Number of Products under Development by Companies, H2 2016 (Contd..11) 156
Number of Products under Development by Companies, H2 2016 (Contd..12) 157
Number of Products under Development by Companies, H2 2016 (Contd..13) 158
Number of Products under Development by Companies, H2 2016 (Contd..14) 159
Number of Products under Development by Companies, H2 2016 (Contd..15) 160
Number of Products under Development by Companies, H2 2016 (Contd..16) 161
Number of Products under Development by Companies, H2 2016 (Contd..17) 162
Number of Products under Development by Companies, H2 2016 (Contd..18) 163
Number of Products under Development by Companies, H2 2016 (Contd..19) 164
Number of Products under Development by Companies, H2 2016 (Contd..20) 165
Number of Products under Development by Companies, H2 2016 (Contd..21) 166
Number of Products under Development by Companies, H2 2016 (Contd..22) 167
Number of Products under Development by Companies, H2 2016 (Contd..23) 168
Number of Products under Development by Companies, H2 2016 (Contd..24) 169
Number of Products under Development by Companies, H2 2016 (Contd..25) 170
Number of Products under Development by Companies, H2 2016 (Contd..26) 171
Number of Products under Development by Companies, H2 2016 (Contd..27) 172
Number of Products under Development by Companies, H2 2016 (Contd..28) 173
Number of Products under Development by Companies, H2 2016 (Contd..29) 174
Number of Products under Development by Companies, H2 2016 (Contd..30) 175
Number of Products under Development by Companies, H2 2016 (Contd..31) 176
Number of Products under Development by Companies, H2 2016 (Contd..32) 177
Number of Products under Development by Companies, H2 2016 (Contd..33) 178
Number of Products under Development by Companies, H2 2016 (Contd..34) 179
Number of Products under Development by Companies, H2 2016 (Contd..35) 180
Number of Products under Development by Companies, H2 2016 (Contd..36) 181
Number of Products under Development by Companies, H2 2016 (Contd..37) 182
Number of Products under Development by Companies, H2 2016 (Contd..38) 183
Number of Products under Development by Companies, H2 2016 (Contd..39) 184
Number of Products under Development by Companies, H2 2016 (Contd..40) 185
Number of Products under Development by Companies, H2 2016 (Contd..41) 186
Number of Products under Investigation by Universities/Institutes, H2 2016 187
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 188
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 189
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 190
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 191
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 192
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 193
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..7) 194
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..8) 195
Comparative Analysis by Late Stage Development, H2 2016 196
Comparative Analysis by Clinical Stage Development, H2 2016 197
Comparative Analysis by Early Stage Development, H2 2016 198
Comparative Analysis by Unknown Stage Development, H2 2016 199
Products under Development by Companies, H2 2016 200
Products under Development by Companies, H2 2016 (Contd..1) 201
Products under Development by Companies, H2 2016 (Contd..2) 202
Products under Development by Companies, H2 2016 (Contd..3) 203
Products under Development by Companies, H2 2016 (Contd..4) 204
Products under Development by Companies, H2 2016 (Contd..5) 205
Products under Development by Companies, H2 2016 (Contd..6) 206
Products under Development by Companies, H2 2016 (Contd..7) 207
Products under Development by Companies, H2 2016 (Contd..8) 208
Products under Development by Companies, H2 2016 (Contd..9) 209
Products under Development by Companies, H2 2016 (Contd..10) 210
Products under Development by Companies, H2 2016 (Contd..11) 211
Products under Development by Companies, H2 2016 (Contd..12) 212
Products under Development by Companies, H2 2016 (Contd..13) 213
Products under Development by Companies, H2 2016 (Contd..14) 214
Products under Development by Companies, H2 2016 (Contd..15) 215
Products under Development by Companies, H2 2016 (Contd..16) 216
Products under Development by Companies, H2 2016 (Contd..17) 217
Products under Development by Companies, H2 2016 (Contd..18) 218
Products under Development by Companies, H2 2016 (Contd..19) 219
Products under Development by Companies, H2 2016 (Contd..20) 220
Products under Development by Companies, H2 2016 (Contd..21) 221
Products under Development by Companies, H2 2016 (Contd..22) 222
Products under Development by Companies, H2 2016 (Contd..23) 223
Products under Development by Companies, H2 2016 (Contd..24) 224
Products under Development by Companies, H2 2016 (Contd..25) 225
Products under Development by Companies, H2 2016 (Contd..26) 226
Products under Development by Companies, H2 2016 (Contd..27) 227
Products under Development by Companies, H2 2016 (Contd..28) 228
Products under Development by Companies, H2 2016 (Contd..29) 229
Products under Development by Companies, H2 2016 (Contd..30) 230
Products under Development by Companies, H2 2016 (Contd..31) 231
Products under Development by Companies, H2 2016 (Contd..32) 232
Products under Development by Companies, H2 2016 (Contd..33) 233
Products under Development by Companies, H2 2016 (Contd..34) 234
Products under Development by Companies, H2 2016 (Contd..35) 235
Products under Development by Companies, H2 2016 (Contd..36) 236
Products under Development by Companies, H2 2016 (Contd..37) 237
Products under Development by Companies, H2 2016 (Contd..38) 238
Products under Development by Companies, H2 2016 (Contd..39) 239
Products under Development by Companies, H2 2016 (Contd..40) 240
Products under Development by Companies, H2 2016 (Contd..41) 241
Products under Development by Companies, H2 2016 (Contd..42) 242
Products under Development by Companies, H2 2016 (Contd..43) 243
Products under Development by Companies, H2 2016 (Contd..44) 244
Products under Development by Companies, H2 2016 (Contd..45) 245
Products under Development by Companies, H2 2016 (Contd..46) 246
Products under Development by Companies, H2 2016 (Contd..47) 247
Products under Development by Companies, H2 2016 (Contd..48) 248
Products under Development by Companies, H2 2016 (Contd..49) 249
Products under Development by Companies, H2 2016 (Contd..50) 250
Products under Development by Companies, H2 2016 (Contd..51) 251
Products under Development by Companies, H2 2016 (Contd..52) 252
Products under Development by Companies, H2 2016 (Contd..53) 253
Products under Development by Companies, H2 2016 (Contd..54) 254
Products under Development by Companies, H2 2016 (Contd..55) 255
Products under Development by Companies, H2 2016 (Contd..56) 256
Products under Development by Companies, H2 2016 (Contd..57) 257
Products under Development by Companies, H2 2016 (Contd..58) 258
Products under Development by Companies, H2 2016 (Contd..59) 259
Products under Development by Companies, H2 2016 (Contd..60) 260
Products under Development by Companies, H2 2016 (Contd..61) 261
Products under Development by Companies, H2 2016 (Contd..62) 262
Products under Development by Companies, H2 2016 (Contd..63) 263
Products under Development by Companies, H2 2016 (Contd..64) 264
Products under Development by Companies, H2 2016 (Contd..65) 265
Products under Investigation by Universities/Institutes, H2 2016 266
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 267
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 268
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 269
Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 270
Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 271
Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 272
Products under Investigation by Universities/Institutes, H2 2016 (Contd..7) 273
Products under Investigation by Universities/Institutes, H2 2016 (Contd..8) 274
Products under Investigation by Universities/Institutes, H2 2016 (Contd..9) 275
Products under Investigation by Universities/Institutes, H2 2016 (Contd..10) 276
Products under Investigation by Universities/Institutes, H2 2016 (Contd..11) 277
Products under Investigation by Universities/Institutes, H2 2016 (Contd..12) 278
Products under Investigation by Universities/Institutes, H2 2016 (Contd..13) 279
Products under Investigation by Universities/Institutes, H2 2016 (Contd..14) 280
Breast Cancer - Pipeline by 3-D Matrix Ltd, H2 2016 281
Breast Cancer - Pipeline by 3-V Biosciences Inc, H2 2016 282
Breast Cancer - Pipeline by 3SBio Inc, H2 2016 283
Breast Cancer - Pipeline by 4SC AG, H2 2016 284
Breast Cancer - Pipeline by A&G Pharmaceutical Inc, H2 2016 285
Breast Cancer - Pipeline by AB Science SA, H2 2016 286
Breast Cancer - Pipeline by AbbVie Inc, H2 2016 287
Breast Cancer - Pipeline by AbGenomics International Inc, H2 2016 288
Breast Cancer - Pipeline by Acceleron Pharma Inc, H2 2016 289
Breast Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 290
Breast Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 291
Breast Cancer - Pipeline by ADC Therapeutics Sarl, H2 2016 292
Breast Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 293
Breast Cancer - Pipeline by Aduro BioTech Inc, H2 2016 294
Breast Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016 295
Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016 296
Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corp, H2 2016 297
Breast Cancer - Pipeline by Advantagene Inc, H2 2016 298
Breast Cancer - Pipeline by Advaxis Inc, H2 2016 299
Breast Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 300
Breast Cancer - Pipeline by Aegis Therapeutics LLC, H2 2016 301
Breast Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 302
Breast Cancer - Pipeline by Aerpio Therapeutics Inc, H2 2016 303
Breast Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016 304
Breast Cancer - Pipeline by Affichem SA, H2 2016 305
Breast Cancer - Pipeline by Agenus Inc, H2 2016 306
Breast Cancer - Pipeline by Agilvax Inc, H2 2016 307
Breast Cancer - Pipeline by Aileron Therapeutics Inc, H2 2016 308
Breast Cancer - Pipeline by Alchemia Ltd, H2 2016 309
Breast Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016 310
Breast Cancer - Pipeline by Alissa Pharma, H2 2016 311
Breast Cancer - Pipeline by Almac Discovery Ltd, H2 2016 312
Breast Cancer - Pipeline by Alteogen Inc, H2 2016 313
Breast Cancer - Pipeline by Amarna Therapeutics BV, H2 2016 314
Breast Cancer - Pipeline by Ambrx Inc, H2 2016 315
Breast Cancer - Pipeline by American Gene Technologies International Inc, H2 2016 316
Breast Cancer - Pipeline by Amgen Inc, H2 2016 317
Breast Cancer - Pipeline by Ampio Pharmaceuticals Inc, H2 2016 318
Breast Cancer - Pipeline by Amplyx Pharmaceuticals Inc, H2 2016 319
Breast Cancer - Pipeline by Angion Biomedica Corp, H2 2016 320
Breast Cancer - Pipeline by ANP Technologies Inc, H2 2016 321
Breast Cancer - Pipeline by AntiCancer Inc, H2 2016 322
Breast Cancer - Pipeline by Antigen Express Inc, H2 2016 323
Breast Cancer - Pipeline by Antoxis Ltd, H2 2016 324
Breast Cancer - Pipeline by Aphios Corp, H2 2016 325
Breast Cancer - Pipeline by APIM Therapeutics AS, H2 2016 326
Breast Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016 327
Breast Cancer - Pipeline by Aravive Biologics Inc, H2 2016 328
Breast Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 329
Breast Cancer - Pipeline by Armour Therapeutics Inc, H2 2016 330
Breast Cancer - Pipeline by Arno Therapeutics Inc, H2 2016 331
Breast Cancer - Pipeline by ArQule Inc, H2 2016 332
Breast Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 333
Breast Cancer - Pipeline by Arvinas Inc, H2 2016 334
Breast Cancer - Pipeline by Asana BioSciences LLC, H2 2016 335
Breast Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016 336
Breast Cancer - Pipeline by AskAt Inc, H2 2016 337
Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 338
Breast Cancer - Pipeline by Astellas Pharma Inc, H2 2016 339
Breast Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 340
Breast Cancer - Pipeline by AstraZeneca Plc, H2 2016 341
List of Figures
Number of Products under Development for Breast Cancer, H2 2016 142
Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2016 143
Number of Products under Development by Companies, H2 2016 144
Number of Products under Investigation by Universities/Institutes, H2 2016 187
Comparative Analysis by Late Stage Development, H2 2016 196
Comparative Analysis by Clinical Stage Development, H2 2016 197
Comparative Analysis by Early Stage Products, H2 2016 198
Assessment by Monotherapy Products, H2 2016 738
Assessment by Combination Products, H2 2016 739
Number of Products by Top 10 Targets, H2 2016 740
Number of Products by Stage and Top 10 Targets, H2 2016 740
Number of Products by Top 10 Mechanism of Actions, H2 2016 783
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 783
Number of Products by Top 10 Routes of Administration, H2 2016 830
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 830
Number of Products by Top 10 Molecule Types, H2 2016 832
Number of Products by Stage and Top 10 Molecule Types, H2 2016 832
